Location: Solmed Polyclinic (Zagreb)
Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.
Main Inclusion Criteria: Patients older than 18 years diagnosed with rheumatoid arthritis for at least 3 months and who, with biological therapy with an anti-TNF* drug, have insufficiently controlled disease.
*anti-TNF drug cannot be adalimumab
Status: Enrolling new patients
Start of patient enrollment: December 2023
Planned completion of patient enrollment: November 2024
